Four clinical sites open, yet no patients dosed this quarter.
Only two patients dosed in all of 2025 — despite eight manufacturing runs completed.
This phase of the trial was supposed to have been completed by now with 15 patients dosed. Instead - only five.
They continue referring to “four patients” when the CEO previously stated Patient 1 was lost to follow-up. Have they re-entered the trial? If so, shareholders deserve an update.
Results Withheld. The company mentions stable disease at five and six months. That’s promising. So why wasn’t an announcement made to the ASX? Look at how Amplia Therapeutics communicates efficacy updates — night and day difference. And the share price reaction? Up over 300%.
Case Western trial: SilenceStill no update on the Case Western trial.
On 19th March 2025, Rebecca stated that a total of four patients had been dosed. This was confirmed in the March Quarterly Report.
So where are the results? We should have had the 28-day, 60-day and 90-day results.
What about the patient with the complete response announced on 7th October 2024?? No updates since then.
There has been a change of Principle Investigator that has not been announced to shareholders.
If management can’t even dose a single patient in three months, how long will it take to reach 15 patients? At this rate — with no clear timeline, poor communication, and total opacity — the company will almost certainly require multiple capital raises, likely followed by a share consolidation. Sound familiar? Just look at Imugene’s trajectory.
CHM Price at posting:
0.3¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)